Stanford's Science paper: AI scientist agents form a virtual biotech for drug discovery
jiqizhixin · x · 2026-11-14
A Stanford-led study published in Science, dubbed Virtual Biotech, retrospectively analyzed 55,984 clinical trials, linking drug-target cell-type specificity to clinical progression and adverse-event rates.
The system organizes specialized AI scientists around a virtual Chief Scientific Officer. The CSO clarifies questions with the user, delegates analyses, and synthesizes findings; specialist agents use domain tools via MCP servers, while a scientific reviewer checks evidence and directs further work when analysis is incomplete. The work supports human-guided research decisions by combining biomedical evidence across disciplines rather than treating a single generated answer as a completed discovery. The released framework exposes code and intermediate research outputs. Cases include target prioritization and a proposed B7-H3 antibody–drug conjugate.
More from coding & agent
- TestPrune: pruning regression tests to unblock AI-driven autonomous bug fixing — burkov · 2026-11-14
- Context beats model choice: Databricks benchmark shows 91% vs 58% for data agents — CautiousUse8597 · 2026-11-14
- Developer skips localhost entirely: prompts go straight to production with AI agent safeguards — marclou · 2026-11-14
- HeyGen MCP demo: one ChatGPT prompt books tickets and sends an avatar birthday video — toolstelegraph · 2026-11-14
- Plenio 2.0: open-source ComfyUI suite turns an idea into a mastered song, now with VST3 — Vivid_Promise1700 · 2026-11-14
- Hallasan Giwon: a reverse-Turing 3D Go & Chess arena you can sneak Claude into via one-line MCP — Responsible-Radio634 · 2026-11-14